Prosigna Breast Cancer Prognostic Gene Signature
2010248
Ordering Recommendation
Assess the risk of distant recurrence in post-menopausal women with early stage (stage I or stage II), hormone receptor-positive (ER+ and/or PR+) breast cancer. Useful in both node-negative and node-positive (1-3 nodes) disease.
Mnemonic
PROSIGNA
Methodology
Hybridization/gene expression
Performed
Varies
Reported
12-14 days  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
  
Collect
Tumor tissue.  
Specimen Preparation
Formalin fix (10 percent neutral buffered formalin) and paraffin embed tissue. Protect from excessive heat. Transport tissue block or 6 unstained 10-micron slides. (Min: 3 slides) Transport block(s) and/or slide(s) in a tissue transport kit (ARUP supply #47808) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787.  
Storage/Transport Temperature
Room temperature or refrigerated. Ship in cooled container during summer months.  
Unacceptable Conditions
Specimens fixed/processed in alternative fixatives (alcohol, Prefer). Decalcified specimens. Less than 10 percent tumor.  
Remarks
Surgical pathology report required.  
Stability
Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable  
Reference Interval
   
Interpretive Data
Refer to report.  
Note
For additional information on Prosigna visit www.aruplab.com/oncology/prosigna.
CPT Code(s)
88381; 81599
Components
Component Test Code*Component Chart Name
2002148Block ID
2010249Prosigna Tumor Size
2010250Prosigna Node Status
2010251Prosigna Risk
2010252Prosigna Score
2010253EER Prosigna Breast Cancer
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • PAM 50
  • PAM50